Current Standards of Chemotherapy for Pancreatic Cancer.
Current Standards of Chemotherapy for Pancreatic Cancer.
复制标题
DOI：
10.1016/j.clinthera.2017.08.015
复制
发表时间：
2017-11
影响因子：
3.2
通讯作者：
Zheng L
中科院分区：
文献类型：
--
作者：
Saung MT;Zheng L
胰腺癌由于早期发展为全身性转移性疾病，预后不佳。化疗是唯一能给患者带来有意义益处的全身疗法。我们回顾了最近发表的III期临床试验的文献，这些临床试验的结果指导了目前胰腺癌化疗的标准。尽管对于转移性胰腺癌和手术切除后的辅助化疗，联合化疗方案均优于吉西他滨单药治疗，但应该认识到，所有联合化疗方案的益处都是有限的。此外，缺乏直接比较各种联合化疗方案的临床试验。随着化疗以外的系统性癌症治疗的进展，有必要对这些化疗方案的生物学特性进行更多的研究，以便我们合理、科学地将它们与靶向治疗和免疫治疗相结合。对于目前胰腺癌的治疗，现有的化疗方案在生存率方面显示出适度但统计学上显著的改善。然而，重要的是要避免试验的交叉比较，并根据患者特征和方案的副作用概况选择方案。
Pancreatic cancer has a dismal prognosis due to the early development of systemic metastatic disease. Chemotherapeutics are the only systemic therapies that offer a meaningful benefit to the patients. We reviewed the literature for recently published phase III clinical trials whose results have guided the current standards of chemotherapy for pancreatic cancer. Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreatic cancer and adjuvant chemotherapy following surgical resection, it should be recognized that all the combination chemotherapy regimens only offer limited benefits. In addition, there is a paucity of clinical trials that directly compare the various combination chemotherapy regimens. With the advancement of systemic cancer treatment beyond chemotherapy, it is important to devote more investigation into better understanding the biology of these chemotherapy regimens, such that we combine them with targeted therapeutics and immunotherapeutics in a rational and scientific manner. For the current treatment of pancreatic cancer, the available chemotherapy regimens have shown modest but statistically significant improvements in survival. However, it is important to avoid cross-comparisons of trials and choose regimens based on patient characteristics and side effect profiles of the regimen.
登录
查看更多内容
影响因子：
4.3
作者：
Guion-Dusserre JF;Bertaut A;Ghiringhelli F;Vincent J;Quipourt V;Marilier S;Tharin Z;Bengrine-Lefevre L
通讯作者：
Bengrine-Lefevre L
影响因子：
45.3
作者：
Gill, Sharlene;Ko, Yoo-Joung;Moore, Malcolm
通讯作者：
Moore, Malcolm
影响因子：
24.5
作者：
Heinemann V;Vehling-Kaiser U;Waldschmidt D;Kettner E;Märten A;Winkelmann C;Klein S;Kojouharoff G;Gauler TC;von Weikersthal LF;Clemens MR;Geissler M;Greten TF;Hegewisch-Becker S;Rubanov O;Baake G;Höhler T;Ko YD;Jung A;Neugebauer S;Boeck S
通讯作者：
Boeck S
DOI：
10.1093/jnci/djx030
发表时间：
2017-09-01
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Jemal A;Ward EM;Johnson CJ;Cronin KA;Ma J;Ryerson B;Mariotto A;Lake AJ;Wilson R;Sherman RL;Anderson RN;Henley SJ;Kohler BA;Penberthy L;Feuer EJ;Weir HK
通讯作者：
Weir HK
影响因子：
45.3
作者：
Gourgou-Bourgade, Sophie;Bascoul-Mollevi, Caroline;Conroy, Thierry
通讯作者：
Conroy, Thierry